EXPERT
Dr. Charles Simone, MD
Radiation Oncologist
Charles B. Simone, II, MD, FACRO is a Research Professor and the Chief Medical Officer of the New York Proton Center. He is also a Full Member in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center. He is an internationally recognized expert in the use of proton therapy to treat thoracic malignancies and for reirradiation, and in the development of clinical trial strategies and innovative research in thoracic radiation oncology and stereotactic body radiation therapy. He is a National Institutes of Health, National Science Foundation, and Department of Defense funded investigator who performs clinical and translational research investigating the benefits of proton therapy as part of multi-modality therapy for lung cancer, malignant pleural mesothelioma, and other thoracic malignancies.
Prior to coming to the New York Proton Center, Dr. Simone was Chief of the Thoracic Oncology Service at the Hospital of the University of Pennsylvania, Director of the Penn Mesothelioma and Pleural Program, and Director of Clinical Research and Operations in the Department of Radiation Oncology at Penn. He was then appointed Medical Director of the Maryland Proton Treatment Center, and at the University of Maryland, he also served as Chair of the Clinical Research Committee for their Comprehensive Cancer Center, proton therapy Fellowship Director, and Director of the Stereotactic Radiation Therapy Program. He completed his undergraduate and medical school training at the University of Pennsylvania, internship in internal medicine, and residency training in radiation oncology at the National Cancer Institute, NIH, where he served as chief resident.
Dr. Simone has published >390 peer-reviewed scientific articles and book chapters, given >245 scientific lectures to national and international audiences, and is the national Principal Investigator or Co-Chair of 7 NIH-funded cooperative group trials (4 NRG Oncology, 1 SWOG, 1 ECOG-ACRIN, 1 PCG). He is a three-time winner of the Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award, and he has been elected for Fellowship in the American College of Radiation Oncology (FACRO). Dr. Simone is the Proton Collaborative Group (PCG) President of the Board of Directors and Chairs or Co-Chairs the PCG Executive Committee; PCG Lung Committee; American Society for Radiation Oncology (ASTRO) Lung Resource Panel Committee; ASTRO Small Cell Lung Cancer Guidelines Committee; American Radium Society-American College of Radiology (ARS-ACR) Appropriate Use Criteria Thoracic Committee; Particle Therapy Co-Operative Group (PTCOG) Gastrointestinal Subcommittee; PTCOG Skull Base/Central Nervous System, Sarcoma Subcommittee; American College of Radiation Oncology (ACRO) Recruitment Subcommittee; ACRO Annual Meeting Abstracts Committee; and National Cancer Institute/Radiosurgery Society (RSS) GRID-Lattice-Microbeam-Flash Radiotherapy Clinical Working Group. He is the Editor-in-Chief of Annals of Palliative Medicine and on the Editorial Boards of Journal of Clinical Oncology, Cancers, Journal of Thoracic Disease, Frontiers in Oncology, Translational Lung Cancer Research, Annals of Translational Medicine, and Therapeutic Radiology and Oncology.
Prior to coming to the New York Proton Center, Dr. Simone was Chief of the Thoracic Oncology Service at the Hospital of the University of Pennsylvania, Director of the Penn Mesothelioma and Pleural Program, and Director of Clinical Research and Operations in the Department of Radiation Oncology at Penn. He was then appointed Medical Director of the Maryland Proton Treatment Center, and at the University of Maryland, he also served as Chair of the Clinical Research Committee for their Comprehensive Cancer Center, proton therapy Fellowship Director, and Director of the Stereotactic Radiation Therapy Program. He completed his undergraduate and medical school training at the University of Pennsylvania, internship in internal medicine, and residency training in radiation oncology at the National Cancer Institute, NIH, where he served as chief resident.
Dr. Simone has published >390 peer-reviewed scientific articles and book chapters, given >245 scientific lectures to national and international audiences, and is the national Principal Investigator or Co-Chair of 7 NIH-funded cooperative group trials (4 NRG Oncology, 1 SWOG, 1 ECOG-ACRIN, 1 PCG). He is a three-time winner of the Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award, and he has been elected for Fellowship in the American College of Radiation Oncology (FACRO). Dr. Simone is the Proton Collaborative Group (PCG) President of the Board of Directors and Chairs or Co-Chairs the PCG Executive Committee; PCG Lung Committee; American Society for Radiation Oncology (ASTRO) Lung Resource Panel Committee; ASTRO Small Cell Lung Cancer Guidelines Committee; American Radium Society-American College of Radiology (ARS-ACR) Appropriate Use Criteria Thoracic Committee; Particle Therapy Co-Operative Group (PTCOG) Gastrointestinal Subcommittee; PTCOG Skull Base/Central Nervous System, Sarcoma Subcommittee; American College of Radiation Oncology (ACRO) Recruitment Subcommittee; ACRO Annual Meeting Abstracts Committee; and National Cancer Institute/Radiosurgery Society (RSS) GRID-Lattice-Microbeam-Flash Radiotherapy Clinical Working Group. He is the Editor-in-Chief of Annals of Palliative Medicine and on the Editorial Boards of Journal of Clinical Oncology, Cancers, Journal of Thoracic Disease, Frontiers in Oncology, Translational Lung Cancer Research, Annals of Translational Medicine, and Therapeutic Radiology and Oncology.
18 years
Experience
Dr. Charles Simone, MD
- NEW YORK, NY
- Perelman School of Medicine University of Pennsylvania
- Accepting new patients
The Benefits of Treating Cancer with Proton Therapy
By Dr. Charles B. Simone, II, MD, FACROProton therapy is the most precisely targeted form of radiotherapy currently available to patients. Despite the FDA’s approval of proton...
